Pharmacoeconomics for Dermatologists: An Introduction

1997 ◽  
Vol 1 (3) ◽  
pp. 185-189
Author(s):  
Aditya K. Gupta ◽  
Paul I. Oh ◽  
Neil H. Shear

Background: The budgets available for health care are becoming constrained and health care decision makers have increasingly begun to scrutinize cost along with efficacy, tolerability, and cost of the different treatment options for each disease state. In keeping with the above, there has been a marked increase in the number of pharmacoeconomic evaluations published in the medical literature, including dermatology journals. Methods: Comprehensive economic evaluations systematically consider the following: statement of question, defining relevant costs, perspective and time-horizon, synthesis of data on efficacy and effectiveness, and selection of the appropriate analytic type and framework. The conclusions should be tested through extensive sensitivity analyses. Conclusions: Economic evaluations are becoming more prevalent in the field of dermatology. A well-constructed analysis may be an aid to more rational therapeutic decision-making.

2002 ◽  
Vol 5 (2) ◽  
pp. 71-78 ◽  
Author(s):  
Christiane Hoffmann ◽  
Boyka A. Stoykova ◽  
John Nixon ◽  
Julie M. Glanville ◽  
Kate Misso ◽  
...  

2005 ◽  
Vol 165 (16) ◽  
pp. 1917 ◽  
Author(s):  
Paul R. Billings ◽  
Rick J. Carlson ◽  
Josh Carlson ◽  
Mary Cain ◽  
Charles Wilson ◽  
...  

Surgery ◽  
2020 ◽  
Vol 167 (2) ◽  
pp. 396-403 ◽  
Author(s):  
Brooks V. Udelsman ◽  
Nicolas Govea ◽  
Zara Cooper ◽  
David C. Chang ◽  
Angela Bader ◽  
...  

1997 ◽  
Vol 2 (4) ◽  
pp. 212-216 ◽  
Author(s):  
Niteesh Choudhry ◽  
Pamela Slaughter ◽  
Kathy Sykora ◽  
C. David Naylor

Objectives: To examine funding priorities assigned by health ministry officials when choosing between clinical programs that offer similar overall benefits distributed in different ways (e.g. large gains for a few versus small gains for many), and to compare the relative magnitude of any distributional bias to age biases. Methods: A survey consisting of paired hypothetical health care programs was mailed to the 135 most senior officials of the Health Ministry in Ontario, Canada (population 11.5 million). Respondents were asked to assume they were members of a panel allocating a fixed sum of money to one of two programs in each pair. All program descriptions included the number of persons affected each year by a given disease and the average survival gains from the hypothetical programs. Some scenarios also mentioned the side-effects associated with programs and/or the average age of the beneficiaries. Results: Four respondents had retired/died. Of 131 eligible respondents, 80/131 (61%) provided usable responses. Asked to choose between providing large benefits to a few citizens and small benefits to a great many, 23% (95% CI: 14%, 33%) of respondents were unable to decide, but 55.8% (95% CI: 47%, 70%) favored providing large benefits to fewer patients. Eliminating the 23% unable to decide, 47/62 or 76% (CI: 63%, 86%) expressed a distributional preference. With a smaller distributional discrepancy, indecision increased, with 35% of respondents having no preference and the remainder split almost evenly between the two programs. Other scenarios showed that health officials' pro-youth biases were only slightly larger than their distributional preferences and that distributional preferences were magnified when combined with minor differences in average ages of beneficiaries. Conclusions: A substantial minority of health care decision-makers had difficulty choosing between programs with similar overall gains and distributional differences — a result consistent with the utilitarian assumptions of cost-effectiveness analysis. However, when distributional differences were large, decision-makers clearly favored large gains for a few beneficiaries rather than small gains for many. Policy analysts should explicitly weigh distributional issues along with aggregate health gains when addressing resource allocation problems.


Author(s):  
Michael Drummond ◽  
Arno Brandt ◽  
Bryan Luce ◽  
Joan Rovira

AbstractThere has been an exponential growth in the literature on economic evaluation in health care. As the range and quality of analytical work has improved, economic studies are becoming more influential with health care decision makers. The development of standards for economic evaluation methods would help maintain the scientific quality of studies, facilitate the comparison of economic evaluation results for different health care interventions, and assist in the interpretation of results from setting to setting. However, standardization might unnecessarily stifle methodological developments. This paper reviews the arguments for and against standardization, assesses attempts to date, outlines the main areas of agreement and disagreement on methods for economic evaluation, and makes recommendations for further work.


2021 ◽  
pp. 0272989X2110282
Author(s):  
Laura Bojke ◽  
Marta O. Soares ◽  
Karl Claxton ◽  
Abigail Colson ◽  
Aimée Fox ◽  
...  

Background The evidence used to inform health care decision making (HCDM) is typically uncertain. In these situations, the experience of experts is essential to help decision makers reach a decision. Structured expert elicitation (referred to as elicitation) is a quantitative process to capture experts’ beliefs. There is heterogeneity in the existing elicitation methodology used in HCDM, and it is not clear if existing guidelines are appropriate for use in this context. In this article, we seek to establish reference case methods for elicitation to inform HCDM. Methods We collated the methods available for elicitation using reviews and critique. In addition, we conducted controlled experiments to test the accuracy of alternative methods. We determined the suitability of the methods choices for use in HCDM according to a predefined set of principles for elicitation in HCDM, which we have also generated. We determined reference case methods for elicitation in HCDM for health technology assessment (HTA). Results In almost all methods choices available for elicitation, we found a lack of empirical evidence supporting recommendations. Despite this, it is possible to define reference case methods for HTA. The reference methods include a focus on gathering experts with substantive knowledge of the quantities being elicited as opposed to those trained in probability and statistics, eliciting quantities that the expert might observe directly, and individual elicitation of beliefs, rather than solely consensus methods. It is likely that there are additional considerations for decision makers in health care outside of HTA. Conclusions The reference case developed here allows the use of different methods, depending on the decision-making setting. Further applied examples of elicitation methods would be useful. Experimental evidence comparing methods should be generated.


2017 ◽  
Vol 8 (2) ◽  
Author(s):  
Paul C Langley ◽  
Taeho Greg Rhee

In 2016, a review of modeled cost-effectiveness studies published in Value in Health between January 2015 and December 2015 was presented. The purpose of the review was to consider whether these modeled claims for cost-effectiveness met the standards of normal science: were the claims made credible, evaluable and replicable? The review concluded that none of the 16 studies assessed met this standard. They should be seen as thought experiments; the construction of imaginary worlds which should be categorized as pseudoscience. The reader, or health care decision maker, would have had no idea, and would never know, whether the claims were right, wrong or misleading. Similar reviews were undertaken in Pharmacoeconomics and the Journal of Medical Economics and came to the same conclusion. The purpose of this second review is to consider the modeled claims published in Value in Health between January 2016 and December 2016, applying the same criteria. Unfortunately, for those who subscribe to the standards of normal science, we must come to the same conclusion. Of the 13 economic evaluations reviewed, 12 simulated claims that were immune to failure. The model structures ensured that the claims were neither evaluable nor replicable. They were categorized as pseudoscience; they failed to meet the standards of normal science. Five of these studies were supported by manufacturers and all supported the manufacturer’s product. Three systematic reviews were also evaluated. Once again, there was a failure to consider meeting the standards of normal science in presenting modeled claims for cost-effectiveness.   Type: Commentary


Sign in / Sign up

Export Citation Format

Share Document